- Home
- TNMG vs CANF Comparison
TNMG vs CANF Comparison
Compare TNMG & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNMG
- CANF
- Stock Information
- Founded
- TNMG 2023
- CANF 1994
- Country
- TNMG Japan
- CANF Israel
- Employees
- TNMG N/A
- CANF 5
- Industry
- TNMG
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- TNMG
- CANF Health Care
- Exchange
- TNMG NYSE
- CANF Nasdaq
- Market Cap
- TNMG 9.2M
- CANF 14.8M
- IPO Year
- TNMG N/A
- CANF N/A
- Fundamental
- Price
- TNMG $0.30
- CANF $1.11
- Analyst Decision
- TNMG
- CANF Strong Buy
- Analyst Count
- TNMG 0
- CANF 2
- Target Price
- TNMG N/A
- CANF $14.00
- AVG Volume (30 Days)
- TNMG 858.4K
- CANF 452.5K
- Earning Date
- TNMG 05-01-2025
- CANF 05-20-2025
- Dividend Yield
- TNMG N/A
- CANF N/A
- EPS Growth
- TNMG N/A
- CANF N/A
- EPS
- TNMG N/A
- CANF N/A
- Revenue
- TNMG $48,493,897.00
- CANF $674,000.00
- Revenue This Year
- TNMG N/A
- CANF $461.72
- Revenue Next Year
- TNMG N/A
- CANF N/A
- P/E Ratio
- TNMG N/A
- CANF N/A
- Revenue Growth
- TNMG N/A
- CANF N/A
- 52 Week Low
- TNMG $0.26
- CANF $1.02
- 52 Week High
- TNMG $34.08
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- TNMG N/A
- CANF 40.05
- Support Level
- TNMG N/A
- CANF $1.02
- Resistance Level
- TNMG N/A
- CANF $1.20
- Average True Range (ATR)
- TNMG 0.00
- CANF 0.06
- MACD
- TNMG 0.00
- CANF 0.01
- Stochastic Oscillator
- TNMG 0.00
- CANF 40.91
About TNMG TNL MEDIAGENE
TNL Mediagene is a comprehensive media and data platform providing news and commentary on current events, business, technology, lifestyle and sports.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).